SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 213 filers reported holding SAGE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,663,986 | +1107.9% | 77,924 | +879.8% | 0.01% | +550.0% |
| Q4 2022 | $303,327 | -76.2% | 7,953 | -72.3% | 0.00% | -87.5% |
| Q3 2021 | $1,272,000 | +54.6% | 28,697 | +98.1% | 0.02% | +77.8% |
| Q2 2021 | $823,000 | -82.8% | 14,489 | -77.3% | 0.01% | -88.2% |
| Q1 2021 | $4,783,000 | +257.2% | 63,907 | +313.0% | 0.08% | +300.0% |
| Q4 2020 | $1,339,000 | +74.3% | 15,475 | -42.1% | 0.02% | -40.6% |
| Q1 2020 | $768,000 | – | 26,738 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |